1. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus;Esteban, J.I.; Lopez-Talavera, J.C.; Genesca, J.; Madoz, P.; Viladomiu, L.; Muniz, E.;Ann Intern Med,1991
2. The natural history of community-acquired hepatitis C in the United States;Alter, M.J.; Margolis, H.S.; Krawczynski, K.; Judson, F.N.; Mares, A.; Alexander, W.J.;N EngltJMed,1992
3. Viral Hepatitis;McQuillan, G.M.; Alter, M.J.; Everhart, J.E.;Government Printing Office; Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Health Service, NIH, NIDDKD, Washington DC: US,1994
4. Treatment of chronic hepatitis C with recombinant interferon alpha;Davis, G.L.; Balart, L.A.; Schiff, E.R.; Lindsay, K.; Bodenheimer, H.C.; Perrillo, R.P.;N Engl Jf Med,1989
5. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A nonB hepatitis;CausseX, GodinotH; ChevallierM, Chossegros P.; F, Zoulim; D, Ouzan;Gastroenterology,1991